RCT for the Chinese Medicine in Treating Hypercholesterolemia

The Chinese University of Hong Kong

Status and phase: Not yet enrolling; Phase 2

Conditions: Hypercholesterolemia

Treatments: Drug: Dachaihu Decoction combined Erzhiwan with variation; Other: Placebo granules

Study type: Interventional

Funder types: Other

Identifiers

NCT06700408

Hypercholesterolemia study

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.

Full description

Hypercholesterolemia refers to a metabolic disease caused by abnormal cholesterol metabolism in the blood cholesterol content exceeding the normal range, which can be mainly divided into total cholesterol (TC) in plasma and low-density lipoprotein cholesterol LDL-C) or a decrease in high-density lipoprotein cholesterol (HDL-C). Uncontrolled hypercholesterolemia is considered an important risk factor for cardiovascular and cerebrovascular diseases.

In recent years, there has been an increasing number of clinical studies of Traditional Chinese Medicine combinations or single herbs for hypercholesterolemia, and some drugs do have cholesterol-lowering effects, but the clinical evidence is not high due to bias or other deficiencies in trial design. Therefore, this clinical trial aim to evaluate the effectiveness of Dachaihu Decoction combined Erzhiwan with variation to the treatment of patients with clinical hypercholesterolemia, and tried to reduce its adverse effects on liver function through reasonable compatibility.

Enrollment: 70 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-80 years old, any gender;
• LDL-C level of 4.1 mmol/L or above (no statin therapy during the screening period);
• Be able to maintain a more consistent lifestyle and eating habits throughout the study;
• Have a fixed residence and are not expected to move or travel for 8 weeks;
• Voluntarily sign the informed consent form.

Exclusion criteria

• Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);
• Alcohol or drug abuse within the last 3 months;
• Known liver function or renal dysfunction;
• History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;
• Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;
• Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;
• Patients with known secondary hypercholesterolemia.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

70 participants in 2 patient groups, including a placebo group

Dachaihu Decoction combined Erzhiwan with variation granules

Experimental group

Description:

Chinese medicine granules

Treatment:

Drug: Dachaihu Decoction combined Erzhiwan with variation

Placebo granules

Placebo Comparator group

Description:

Placebo granules

Treatment:

Other: Placebo granules